Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2013, Pages 1014-1023

  Rauch, Antoine ^a,b,c,d   Legendre, Paulette ^a,b   Christophe, Olivier D ^a,b   Goudemand, Jenny ^c,d   van Belle, Eric ^c,d   Vincentelli, André ^c,d   Denis, Cécile V ^a,b   Susen, Sophie ^c,d   Lenting, Peter J ^a,b  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

Acquired von Willebrand syndrome; ADAMTS13; Antibody therapy; Circulatory assist devices; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; EPITOPE; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ARTICLE; CHEMOLUMINESCENCE; HEART ASSIST DEVICE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOPRECIPITATION; INTERFEROMETRY; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SHEAR STRESS; THROMBOCYTE FUNCTION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; ANTIGEN ANTIBODY REACTION; BLOOD; BLOOD RHEOLOGY; DOSE RESPONSE; HEMORRHAGE; HEMOSTASIS; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN TERTIARY STRUCTURE; SYNTHESIS;

ADAM PROTEINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES; HEART-ASSIST DEVICES; HEMORHEOLOGY; HEMORRHAGE; HEMOSTASIS; HUMANS; MICE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 84908519520     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-02-0148     Document Type: Article

References (42)

1. Zhou YF, et al. Sequence and structure relationships within von Willebrand factor. Blood 2012; 120: 449-458.
2. Sadler JE. von Willebrand factor assembly and secretion. J Thromb Haemost 2009; 7 (Suppl 1): 24-27.
3. Valentijn KM, et al. Functional architecture of Weibel-Palade bodies. Blood 2011; 117: 5033-5043.
4. Groot E, et al. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 2009; 7: 962-969.
5. De Ceunynck K, et al. Unwinding the von Willebrand factor strings puzzle. Blood 2013; 121: 270-277.
6. Crawley JT, et al. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
7. Gao W, et al. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci USA 2006; 103: 19099-19104.
8. Zanardelli S, et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009; 114: 2819-2828.
9. Feys HB, et al. Multi-step binding of ADAMTS-13 to von Willebrand factor. J Thromb Haemost 2009; 7: 2088-2095.
10. Xiang Y, et al. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci USA 2011; 108: 11602-11607.
11. Tsai HM. von Willebrand factor, shear stress, and ADAMTS13 in haemostasis and thrombosis. ASAIO J 2012; 58: 163-169.
12. Dong JF, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
13. De Ceunynck K, et al. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 2011; 286: 36361-36367.
14. Shim K, et al. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111: 651-657.
15. Levy GG, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
16. Sadler JE, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
17. Warkentin TE, et al. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet 1992; 340: 35-37.
18. Vincentelli A, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349: 343-349.
19. Geisen U, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33: 679-684.
20. Uriel N, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during longterm support and at the time of transplantation. J Am Coll Cardiol 2010; 56: 1207-1213.
21. Crow S, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137: 208-215.
22. Pareti FI, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102: 1290-1295.
23. Meyer AL, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010; 3: 675-681.
24. Thompson JL, 3rd, et al. Risk of recurrent gastrointestinal bleeding after aortic valve replacement in patients with Heyde syndrome. J Thorac Cardiovasc Surg 2012; 144: 112-116.
25. Lenting PJ, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004; 279: 12102-12109.
26. Pegon JN, et al. Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica 2012; 97: 1855-1863.
27. Meyer D, et al. Hybridoma antibodies to human von Willebrand factor. I. Characterisation of seven clones. Br J Haematol 1984; 57: 597-608.
28. Meyer D, et al. Hybridoma antibodies to human von Willebrand factor. II. Relative role of intramolecular loci in mediation of platelet adhesion to the subendothelium. Br J Haematol 1984; 57: 609-620.
29. Rayes J, et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost 2007; 5: 321-328.
30. Han Y, et al. A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura. Transfusion 2011; 51: 1580-1591.
31. Frazier OH, et al. First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report. Tex Heart Inst J 2004; 31: 157-159.
32. Layet S, et al. Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely. Biochem J 1992; 282: 129-137.
33. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012; 125: 3038-3047.
34. Lancellotti S, et al. Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases. Mediterr J Hematol Infect Dis 2013; 5: e2013058.
35. Wu JJ, et al. Characterisation of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci USA 2006; 103: 18470-18474.
36. Zhang J, et al. A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13. PLoS One 2011; 6: e22157.
37. Klaus C, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-4519.
38. Luken BM, et al. The spacer domain of ADAMTS13 contains a major binding site for antibodies in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2005; 93: 267-274.
39. Blackshear JL, et al. Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy. Mayo Clin Proc 2011; 86: 219-224.
40. Favaloro EJ, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients: a rebuttal. J Thromb Haemost 2012; 10: 1455-1458.
41. Rolf N, et al. Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia. Thromb Haemost 2010; 103: 1272-1274.
42. Heilmann C, et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012; 38: 62-68.